Emerging Business Tools
practice areas
honors + affiliations
Member, American Bar Association, Business Law Section
Listed as Recommended in Life Sciences Commercial and Partnering by PLC Cross-border Life Sciences Handbook (2007/2008)
Listed, Chambers USA: America's Leading Lawyers for Business (2006, 2008–2011)
Listed as Recommended in Life Sciences Commercial and Partnering, PLC Which Lawyer? Yearbook 2008
Listed, New Jersey Super Lawyers (2005–2009)
Recipient, Philadelphia Business Journal Inaugural Life Sciences Award for Best Consultant (Later Stage) (2010)
bar admissions
- New Jersey
- Pennsylvania
- New York
- Missouri
- Princeton
-
502 Carnegie Center
Princeton, NJ 08540-6289
Phone: 609.919.6606
Fax: 609.919.6701
Randall B. Sunberg is a partner in Morgan Lewis's Business and Finance Practice, vice chair of the firm's Life Sciences Interdisciplinary Group, co-chair of the firm's Life Sciences Transactions Practice, and Managing Partner of the Princeton office.
Mr. Sunberg's clients range from early-stage biotechnology start-ups to global pharmaceutical companies, as well as specialty pharma, medical device, diagnostics, and other technology companies. He also advises private equity, venture capital, and investment banking firms focused on the life sciences industry. Mr. Sunberg's background includes a variety of transactions, including negotiating and structuring complex collaborations, mergers and acquisitions, divestitures, joint ventures, corporate partnering and licensing, and the equity investments that often accompany such transactions. Related matters include: alternative financing arrangements such as royalty monetizations; technical contractual arrangements for drug discovery, development, manufacturing and supply; marketing and co-promotion transactions; and outsourcing in the life sciences industry. He also advises boards of directors and significant shareholders on disclosure issues, corporate communications policies, and fiduciary duty matters.
Mr. Sunberg has spoken on the subjects of mergers and acquisitions, strategic alliances, and licensing and collaboration transactions in the United States at Allicense, BIO Annual Meetings and LES Annual Meetings, in Canada at BIOMedex, and in China at BIOForum, as well as at other life-sciences-related conferences and as guest lecturer at the Rutgers Business School MBA Biotechnology Commercialization Concentration.
Mr. Sunberg is admitted to practice in New Jersey, Pennsylvania, New York, and Missouri.
Selected Representations
- Shire in its co-development and co-commercialization agreement with Shionogi for certain of Shire's ADHD medicines in Japan
- Lundbeck in its up to $1.8 billion co-development and co-commercialization global alliance with Otsuka Pharmaceutical for up to five innovative psychiatric and neuroscience products worldwide
- Eli Lilly in its transfer of U.S. rights to sepsis drug Xigris® to BioCritica, a newly created biotech company jointly owned by Lilly, Care Capital, and NovaQuest Capital
- ViroPharma in its global collaboration and licensing agreement for the subcutaneous combination of Cinryze® (C1 esterase inhibitor [human]) with Halozyme Therapeutics' recombinant human hyaluronidase enzyme (rHuPH20) EnhanzeTM technology
- Takeda in its up to $750 million development and commercialization collaboration with Intra-Cellular Therapies on selective PDE1 inhibitors for cognitive impairment associated with schizophrenia
- Lundbeck in its donation together with Novartis of their rights to compound Lu AE58479 for SSADH deficiency to the National Institutes of Health
- Auxilium Pharmaceuticals in its up to $262 million development, commercialization, and supply collaboration with Asahi Kasei for Xiaflex® in Japan
- Lundbeck in its drug discovery collaborations with Zenobia Therapeutics and Vernalis plc for inhibitors for LRRK2
- Invida Group in its exclusive licensing and distribution collaboration with Orexo AB covering the Pacific region for Abstral™
- Lundbeck in its development and commercialization collaboration agreement with Kyowa Hakko Kirin relating to adenosine A2A antagonist products outside of Japan and the Asia region for all fields, including Parkinson's disease
- Onyx Pharmaceuticals in its more than $300 million development and commercialization collaboration with Ono Pharmaceutical for Carfilzomib and ONX-0912 in oncology indications in Japan
- Concordia Pharmaceuticals in its licensing agreement with Ono Pharmaceutical to develop and commercialize salirasib, an agent for the treatment of pancreatic, non-small cell lung and colorectal cancers, in Japan
- Diamyd Medical AB in its up to $625 million license, development, and commercialization agreement with Ortho-McNeil-Janssen Pharmaceuticals focused on GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditions
- GlaxoSmithKline in its up to $1.58 billion antisense drug collaboration with Isis Pharmaceuticals for the development and commercialization of therapeutics for rare and infectious diseases
- Biovail in its acquisition of certain AMPAKINE® compounds and associated intellectual property from Cortex Pharmaceuticals
- Smiths Detection in its collaboration with Novartis Diagnostics relating to Smiths' Bio-Seeq platform and LATE-PCR technology for use in a range of point-of-care diagnostic tests
- NPS Pharmaceuticals in the sale of its royalty rights from sales in Asia of REGPARA to a fund managed by DRI Capital for $38.4 million
- Auxilium Pharmaceuticals in its up to $485 million development, commercialization, and supply collaboration with Pfizer for Xiaflex® in Europe and Eurasia.
- Profectus BioSciences in the worldwide transfer of Wyeth's therapeutic and prophylactic DNA and vectored vaccine programs for HIV, including NIH contracts providing multimillion dollar funding, as well as HCV, HPV, HSV, and Malaria.
- Immunomedics in its up to $620 million development and commercialization collaboration with Nycomed for the subcutaneous formulation of its humanized anti-CD20 antibody in non-cancer
- Takeda in its $100 million up-front and up to $1 billion development and commercialization collaboration and technology transfer transaction with Alnylam relating to RNAi therapeutics
- Lundbeck in its $100 million up-front and up to $250 million in connection with regulatory approvals, development and commercialization collaboration with Myriad for the Alzheimer's disease drug Flurizan
- Shire in its up to $325 million development and commercialization collaboration with Alba Therapeutics for gastrointestinal permeability inhibitor AT-1001
- Adolor in its up to $265 million development and commercialization collaboration with Pfizer for delta opioid agonists
- Acura Pharmaceuticals in its development and commercialization collaboration with King Pharmaceuticals for opioid analgesic products
- Shire in its up to $440 million genetic disorders development and commercialization collaboration with Amicus Therapeutics
- NPS Pharmaceuticals in its licensing collaboration with Nycomed for Gattex
- Cardiokine in its up to $220 million development and commercialization collaboration with Biogen Idec for lixivaptan, a selective V2 vasopressin receptor agonist
- Shire in its up to $825 million development and commercialization collaboration with Renovo for Juvista (human TGFß3)
- Merck in its divestiture of several marketed products to Iroko Pharmaceuticals
- Lundbeck in its acquisition of Saegis Pharmaceuticals
- Ambrilia Biopharma in its up to $232 million worldwide licensing agreement with Merck relating to its HIV/AIDS protease inhibitor program
- Cytogen in the sale of its 50% joint venture interest in the conjugated antibody development and commercialization collaboration, PSMA Development Company LLC, to Progenics
- Schering-Plough in its global collaboration with Novartis to develop and commercialize a once-daily inhaled fixed-dose combination therapy for asthma and COPD
- Pharmasset in its development and commercialization collaboration with Bukwang Pharmaceuticals of Korea for the treatment of chronic hepatitis B virus
- Biovail Pharmaceuticals in its more than $100 million product divestiture, strategic collaboration and research and development alliance with Kos Pharmaceuticals in the area of cardiovascular disease
- Shire in its up to $500 million collaboration with New River Pharmaceuticals for the development and commercialization of a late-stage ADHD compound
- Schering-Plough in its acquisition of Bayer AG's primary care pharmaceutical product business in the United States and related strategic alliances on oncology products and on Zetia® in Japan
- Paul Royalty Fund in its revenue monetization and equity investment in Verus Pharmaceuticals
- Sanofi-Aventis in the restructuring of its Actonel® collaboration with Procter & Gamble
- Sanofi-Aventis in its up to $115 million royalty monetization transaction with Paul Royalty Fund relating to sales of Lunesta® by Sepracor
- Pharmasset in its $300 million collaboration with Roche to develop and commercialize nucleoside polymerase inhibitors for the treatment of chronic hepatitis C virus infections
- Sanofi-Aventis in its up to $485 million collaboration with Regeneron to develop and commercialize VEGF-Trap products, and related equity investment
- Quintiles in its co-development and co-promotion collaboration with Eli Lilly for Cymbalta®
- Cephalon in its $444 million stock-for-stock acquisition of Anesta
- Sanofi-Aventis in its collaboration with ImmunoGen to discover, develop and commercialize novel antibody-based oncology products
- Adolor in its worldwide development and commercialization collaboration for Entereg® with GlaxoSmithKline
- Arena Pharmaceuticals in its drug discovery collaboration with Merck
- Sanofi-Aventis in its inhaled insulin strategic alliance with Pfizer and related collaboration and licensing arrangements with Nektar Therapeutics
education
- New York University School of Law, 1982, J.D.
- Yale University, 1977, B.A.